EMEA-000980-PIP01-10-M05

Key facts

Invented name
Adcetris
Active substance
Brentuximab vedotin
Therapeutic area
Oncology
Decision number
P/0232/2017
PIP number
EMEA-000980-PIP01-10-M05
Pharmaceutical form(s)
Powder for concentrate for solution for infusion
Condition(s) / indication(s)
  • Treatment of anaplastic large cell lymphoma
  • Treatment of Hodgkin lymphoma
Route(s) of administration
Intravenous use
Contact for public enquiries
Takeda Pharma A/S
United Kingdom
Tel. +44 (0)2031 168000
E-mail: paediatrics@tgrd.com
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating